StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
December 7, 2021 5:15 AM
Oppenheimer analyst Jay Olson raised the price target on Acadia Pharmaceuticals (NASDAQ:
ACAD
) to $23.00 (from $20.00) while maintaining a Perform rating.
Categories
Analyst PT Change
Next Articles
Acadia Pharma (ACAD) Stock Soars on Positive Rett Syndrome Results, Analysts Still Not Convinced
December 7, 2021 8:17 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs
December 7, 2021 6:39 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho Securities
December 7, 2021 6:30 AM
Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst
December 7, 2021 6:14 AM
